12583-68-5

Active fragment (1-34) of endogenous human parathyroid hormone:
Treatment of osteoporosis in postmenopausal women and men at increased risk of fractures
Treatment of corticosteroid-induced osteoporosis

Teriparatide, parathyroid hormone (1–34), is the only anabolic agent available in the United States for the treatment of postmenopausal osteoporosis. Side effects that human should report to doctor or health care professional as soon as possible:
allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
blood in the urine; pain in the lower back or side; pain when urinating
signs and symptoms of low blood pressure like dizziness; feeling faint or lightheaded, falls; unusually weak or tired
signs and symptoms of increased calcium like nausea; vomiting; constipation; low energy; or muscle weakness

No metabolism or excretion studies have been performed. Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%).